Dr. Paul F. Lizzul Net Worth

The estimated Net Worth of Paul F. Lizzul is at least $825 Thousand dollars as of 14 August 2024. Dr Lizzul owns over 2,000 units of AnaptysBio Inc stock worth over $484,801 and over the last 7 years he sold ANAB stock worth over $0. In addition, he makes $339,765 as Chief Medical Officer at AnaptysBio Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Dr Lizzul ANAB stock SEC Form 4 insiders trading

Dr has made over 5 trades of the AnaptysBio Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 2,000 units of ANAB stock worth $37,000 on 14 August 2024.

The largest trade he's ever made was buying 10,000 units of AnaptysBio Inc stock on 1 August 2017 worth over $150,000. On average, Dr trades about 1,350 units every 135 days since 2017. As of 14 August 2024 he still owns at least 13,618 units of AnaptysBio Inc stock.

You can see the complete history of Dr Lizzul stock trades at the bottom of the page.

Dr. Paul F. Lizzul biography

Dr. Paul F. Lizzul is the Chief Medical Officer at AnaptysBio Inc.

What is the salary of Dr Lizzul?

As the Chief Medical Officer of AnaptysBio Inc, the total compensation of Dr Lizzul at AnaptysBio Inc is $339,765. There are 4 executives at AnaptysBio Inc getting paid more, with Hamza Suria having the highest compensation of $7,875,190.

How old is Dr Lizzul?

Dr Lizzul is 46, he's been the Chief Medical Officer of AnaptysBio Inc since . There are 11 older and 3 younger executives at AnaptysBio Inc. The oldest executive at AnaptysBio Inc is Hollings Renton, 73, who is the Lead Independent Director.

What's Dr Lizzul's mailing address?

Paul's mailing address filed with the SEC is 30699 Russell Ranch Rd Suite 140, Westlake Village, CA 91362, USA.

Insiders trading at AnaptysBio Inc

Over the last 8 years, insiders at AnaptysBio Inc have traded over $37,024,151 worth of AnaptysBio Inc stock and bought 5,919,575 units worth $115,520,117 . The most active insiders traders include Holdings A/S Novo, Capital, Llc Eco R1, and James N Topper. On average, AnaptysBio Inc executives and independent directors trade stock every 40 days with the average trade being worth of $4,143,306. The most recent stock trade was executed by Paul F. Lizzul on 14 August 2024, trading 2,000 units of ANAB stock currently worth $37,000.

What does AnaptysBio Inc do?

founded in 2005, anaptysbio, inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (shm) for antibody discovery and optimization. anaptysbio is building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. anaptysbio’s proprietary shm-xel platform, which couples fully human antibody libraries with in vitro somatic hypermutation (shm) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. by harnessing the natural mechanism of antibody maturation under controlled conditions, shm-xel allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. the c

Complete history of Dr Lizzul stock trades at AnaptysBio Inc

AnaptysBio Inc executives and stock owners

AnaptysBio Inc executives and other stock owners filed with the SEC include:

• Hamza Suria,
  President, Chief Executive Officer, Director
• Eric Loumeau,
  Chief Operating Officer, General Counsel
• Hamza Suria,
  Pres, CEO & Director
• Dennis M. Mulroy,
  Chief Financial Officer
• Dr. Paul F. Lizzul,
  Chief Medical Officer
• James Topper,
  Independent Chairman of the Board
• Dennis Fenton,
  Independent Director
• Hollings Renton,
  Lead Independent Director
• J. Anthony Ware,
  Independent Director
• John Schmid,
  Independent Director
• Laura Hamill,
  Independent Director
• Paul Lizzul,
  Chief Medical Officer
• Dennis Mulroy,
  Chief Financial Officer
• Eric J. Loumeau,
  COO & Gen. Counsel
• David McKeon,
  VP & Controller
• Dr. Margaret Marino,
  Sr. VP of Project Management
• Beth Mueller,
  Sr. VP of HR
• Nicholas Lydon,
  Director
• Carol Giltner Gallagher,
  Director
• Matthew Moyle,
  Chief Scientific Officer
• James A Schoeneck,
  Director
• Dominic Piscitelli,
  Chief Financial Officer
• Marco Londei,
  Chief Medical Officer
• Healthcare Vii, L.P.Frazier...,
  
• Healthcare V, Lpfhm V, Lpfh...,
  
• Holdings A/S Novo,
  10% owner
• Ventures Vii L Pavalon Vent...,
  
• John A Orwin,
  
• Magda Marquet,
  
• Rita Jain,
  
• Capital, Llcnodelman Oleg E...,
  
• Capital, Llc Eco R1,
  10% owner
• Daniel Faga,
  CEO